We’re excited to announce that our proprietary platform plato? has been selected as the winner in the Technology Innovation category of the 2021 #FierceInnovation Awards Life Sciences Edition!
AVROBIO
生物技术研究
Cambridge，Massachusetts 18,137 位关注者
Clinical-stage lentiviral gene therapy company, powered by plato?. Our vision: bring personalized gene therapy worldwide
关于我们
Our vision is to bring personalized gene therapy to the world. We target the root cause of genetic disease by introducing a functional copy of the affected gene into patients’ own hematopoietic stem cells (HSCs), with the goal of durably expressing the therapeutic protein throughout the body, including the central nervous system. Our first-in-class pipeline includes clinical programs for Gaucher disease and Hunter syndrome, as well as a preclinical program for Pompe disease. Our proprietary plato? gene therapy platform is scalable for planned global commercialization. We are headquartered in Cambridge, Mass. For additional information, visit avrobio.com, and follow us on Twitter and LinkedIn.
- 网站
-
https://www.avrobio.com
AVROBIO的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Cambridge，Massachusetts
- 类型
- 上市公司
- 领域
- Gene Therapy和Rare Disease
地点
-
主要
获取路线
100 Technology Sq
6th Floor
US，Massachusetts，Cambridge，02139
AVROBIO员工
-
Bruce Booth
Partner at Atlas Venture
-
Mathews Adera, MD
Vice President Clinical Development, AVROBIO Inc
-
Joseph Davis
Information Technology Leader
-
Ingrid Damacela
Manufacturing and Technology Operations Leader (MS&T) | Cell and Gene Therapy | CDMO Management | CMC | Process Improvement | GMP MFG |…